We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Plasminogen Stimulates Formation of Pathogenic Prion Clumps

By LabMedica International staff writers
Posted on 23 Jan 2011
Researchers have found that plasminogen, a protein used by the body to digest blood clots, stimulates the formation of prion clumps, abnormal protein formations that underlie chronic brain diseases such as bovine spongiform encephalopathy (mad cow disease) in cattle; Creutzfeldt-Jakob disease in humans; scrapie in sheep; and chronic wasting disease in cervids.

In order to study the relationship between prions and plasminogen, investigators at the University of Kentucky (Lexington, USA) conducted functional assays using a cell-free prion protein (PrP) conversion system known as protein misfolding cyclic amplification (PMCA) as well as looking at plasminogen in prion-infected cell lines.

They reported in the December 2010 issue of the FASEB Journal that plasminogen stimulated propagation of the protease-resistant scrapie PrP. More...
Compared to control PMCA conducted without plasminogen, addition of plasminogen in PMCA using wild-type brain material significantly increased PrP conversion. PrP conversion in PMCA was substantially less efficient with plasminogen-deficient brain material than with wild-type material.
Stimulation of PrP conversion was specific for plasminogen and depended on plasminogen's kringle domains. This activity was eliminated by modification of plasminogen structure or interference with the PrP-plasminogen interaction. When added to cell cultures, plasminogen and kringles were found to promote PrP propagation in ScN2a and Elk 21+ cells.

"I hope that our study will aid in developing therapy for prion diseases, which will ultimately improve the quality of life of patients suffering from prion diseases," said senior author Dr. Chonsuk Ryou, professor of microbiology, immunology, and molecular genetics at the University of Kentucky. "Since prion diseases can lay undetected for decades, delaying the ability of the disease-associated prion protein to replicate by targeting the cofactor of the process could be a monumental implication for treatment."

Related Links:
University of Kentucky


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.